No Data
Joincare Pharmaceutical Group Industry (600380.SH): Progesterone injection has received registration approval.
On March 24, the company announced that its controlling subsidiary LIVZON PHARMA Group Co., Ltd. (hereinafter referred to as Livzon Pharmaceutical Group Inc.) has received the "Pharmaceutical Registration Certificate" (certificate number: 2025S00728) issued by the National Medical Products Administration, and the progesterone injection has been approved for market release. The application for marketing authorization for the progesterone injection was submitted in April 2023, with the acceptance number: CYHS2301111. The indication for the progesterone injection is for supplemental treatment of progesterone in Assisted Reproduction technology (ART).
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Joincare Pharmaceutical Group IndustryLtd (SHSE:600380) Has A Rock Solid Balance Sheet
Joincare Pharmaceutical Group Industry (600380.SH): has already applied the world's most advanced AI models such as Deepseek in the research and development of Innovative Drugs.
On March 14, Gelonghui reported that Joincare Pharmaceutical Group Industry (600380.SH) stated on the interactive investor platform that the company has always attached great importance to the application of AI technology in drug development and has already utilized the most advanced global AI models such as Deepseek in the research and development of Innovative Drugs. This includes key areas such as target discovery, compound screening, molecular design, pharmaceutical research, and clinical research, aiming to reduce development costs and comprehensively improve research efficiency through cutting-edge Technology.
Joincare Pharmaceutical Group Industry (600380.SH): has fully applied DeepSeek.
Gelonghui reported on March 10 that Joincare Pharmaceutical Group Industry (600380.SH) stated on the interactive platform that DeepSeek has been fully applied and suggestions regarding DeepSeek will be seriously considered. Regarding the company's market communication and information disclosure, the company has maintained a proactive and standardized attitude. In 2024, the company issued a total of 199 announcement documents, more than 96% of A-share listed companies, to ensure that investors can understand the company's dynamics in a timely and comprehensive manner. Moreover, the company has also achieved significant results in information disclosure and investor relations management, and has been awarded by the Shanghai Stock Exchange for four consecutive years.
Joincare Pharmaceutical Group Industry (600380.SH): has repurchased a total of 2.34% of shares.
On March 3, Glonghui reported that Joincare Pharmaceutical Group Industry (600380.SH) announced that by February 2025, the company had repurchased a total of 992,800 shares through centralized bidding, accounting for 0.05% of the total share capital (1,874,200,420 shares), with the highest purchase price at 11.05 yuan/share, the lowest at 10.81 yuan/share, and a total amount paid of 10.8583 million yuan (including fees). As of the end of February 2025, the company had cumulatively repurchased 43,843,462 shares, accounting for the total share capital (1,874,200,420 shares).
Are Strong Financial Prospects The Force That Is Driving The Momentum In Joincare Pharmaceutical Group Industry Co.,Ltd.'s SHSE:600380) Stock?
